Tixagevimab Terminated Phase 2 Trials for Coronavirus Disease 2019 (COVID‑19) Prevention

IndicationsStatusPurposePhase
TerminatedPrevention2
clinicaltrials.gov IdentifierTitleDrugs
NCT05375760A Randomized, Open-label, Dose-ranging Study in Adults and Pediatric Individuals ≥ 12 Years of Age to Assess the Safety, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AZD7442, for Pre-exposure Prophylaxis of COVID-19